WO2003013498A3 - Nitratester-cyclodextrinkomplexe zur behandlung von erkrankungen insbesondere koronarerkrankungen - Google Patents

Nitratester-cyclodextrinkomplexe zur behandlung von erkrankungen insbesondere koronarerkrankungen Download PDF

Info

Publication number
WO2003013498A3
WO2003013498A3 PCT/DE2002/002666 DE0202666W WO03013498A3 WO 2003013498 A3 WO2003013498 A3 WO 2003013498A3 DE 0202666 W DE0202666 W DE 0202666W WO 03013498 A3 WO03013498 A3 WO 03013498A3
Authority
WO
WIPO (PCT)
Prior art keywords
diseases
cyclodextrin complexes
nitrate ester
particularly coronary
treating diseases
Prior art date
Application number
PCT/DE2002/002666
Other languages
English (en)
French (fr)
Other versions
WO2003013498A2 (de
Inventor
Walter Heinzelmann
Stephan Bojar
Cornelius Ruloff
Original Assignee
Dynamit Nobel Gmbh
Walter Heinzelmann
Stephan Bojar
Cornelius Ruloff
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dynamit Nobel Gmbh, Walter Heinzelmann, Stephan Bojar, Cornelius Ruloff filed Critical Dynamit Nobel Gmbh
Priority to AU2002331527A priority Critical patent/AU2002331527A1/en
Priority to JP2003518507A priority patent/JP2004536888A/ja
Priority to EP02767047A priority patent/EP1411915A2/de
Priority to US10/483,219 priority patent/US20040198698A1/en
Priority to HU0401424A priority patent/HUP0401424A3/hu
Priority to PL02365225A priority patent/PL365225A1/xx
Publication of WO2003013498A2 publication Critical patent/WO2003013498A2/de
Publication of WO2003013498A3 publication Critical patent/WO2003013498A3/de
Priority to US11/973,780 priority patent/US20080091006A1/en

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nanotechnology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Die vorliegende Erfindung beschreibt 1:1-Komplexe von organischen Nitratestern mit Cyclodextrinen, die Herstellung dieser Komplexe und Verwendung derselben in der Koronarmedizin.
PCT/DE2002/002666 2001-07-20 2002-07-19 Nitratester-cyclodextrinkomplexe zur behandlung von erkrankungen insbesondere koronarerkrankungen WO2003013498A2 (de)

Priority Applications (7)

Application Number Priority Date Filing Date Title
AU2002331527A AU2002331527A1 (en) 2001-07-20 2002-07-19 Nitrate ester-cyclodextrin complexes for treating diseases, particularly coronary diseases
JP2003518507A JP2004536888A (ja) 2001-07-20 2002-07-19 硝酸エステル−シクロデキストリン錯体
EP02767047A EP1411915A2 (de) 2001-07-20 2002-07-19 Nitratester-cyclodextrinkomplexe zur behandlung von erkrankungen, insbesondere koronarerkrankungen
US10/483,219 US20040198698A1 (en) 2001-07-20 2002-07-19 Nitrate ester-cyclodextrin complexes
HU0401424A HUP0401424A3 (en) 2001-07-20 2002-07-19 Nitrate ester-cyclodextrin complexes
PL02365225A PL365225A1 (en) 2001-07-20 2002-07-19 Nitrate ester-cyclodextrin complexes for treating diseases, particularly coronary diseases
US11/973,780 US20080091006A1 (en) 2001-07-20 2007-10-10 Nitrate ester cyclodextrin complexes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10134683 2001-07-20
DE10134683.2 2001-07-20

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/973,780 Continuation US20080091006A1 (en) 2001-07-20 2007-10-10 Nitrate ester cyclodextrin complexes

Publications (2)

Publication Number Publication Date
WO2003013498A2 WO2003013498A2 (de) 2003-02-20
WO2003013498A3 true WO2003013498A3 (de) 2003-05-22

Family

ID=7692053

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE2002/002666 WO2003013498A2 (de) 2001-07-20 2002-07-19 Nitratester-cyclodextrinkomplexe zur behandlung von erkrankungen insbesondere koronarerkrankungen

Country Status (7)

Country Link
US (2) US20040198698A1 (de)
EP (1) EP1411915A2 (de)
JP (1) JP2004536888A (de)
AU (1) AU2002331527A1 (de)
HU (1) HUP0401424A3 (de)
PL (1) PL365225A1 (de)
WO (1) WO2003013498A2 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9550827B2 (en) 2007-10-19 2017-01-24 The Regents Of The University Of California Methods for ameliorating and preventing central nervous system inflammation

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4073931A (en) * 1974-03-27 1978-02-14 Teijin Limited Nitroglycerine inclusion compounds with cyclodextrin and composition containing same
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US5403828A (en) * 1992-08-13 1995-04-04 American Maize-Products Company Purification of cyclodextrin complexes

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4073931A (en) * 1974-03-27 1978-02-14 Teijin Limited Nitroglycerine inclusion compounds with cyclodextrin and composition containing same
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US5403828A (en) * 1992-08-13 1995-04-04 American Maize-Products Company Purification of cyclodextrin complexes

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE CHEMICAL ABSTRACT [online] 28 February 1986 (1986-02-28), RICHTER, GEDEON, VEGYESZETI GYAR RT., HUNG.: "Preparation of the complex of isosorbide 2,5-dinitrate cyclodextrin as coronary vasodilator", XP002225618, Database accession no. 106:143984 CA *
DATABASE CHEMICAL ABSTRACT [online] 28 June 1980 (1980-06-28), CHINOIN GYOGYSZER ES VEGYESZETI TERMEKEK GYARA RT., HUNG.: "Explosion-proof, tabletable .beta.-cyclodextrin nitroglycerin complexes", XP002225619, Database accession no. 94:162749 CA *
STADLER-SZOKE, AGNES ET AL: "Inclusion complex of nitroglycerin -.beta.-cyclodextrin", ACTA PHARMACEUTICA HUNGARICA (1979), 49(1), 30-4, 1979, XP009002665 *

Also Published As

Publication number Publication date
EP1411915A2 (de) 2004-04-28
US20040198698A1 (en) 2004-10-07
JP2004536888A (ja) 2004-12-09
HUP0401424A3 (en) 2008-03-28
HUP0401424A2 (hu) 2004-11-29
US20080091006A1 (en) 2008-04-17
AU2002331527A1 (en) 2003-02-24
PL365225A1 (en) 2004-12-27
WO2003013498A2 (de) 2003-02-20

Similar Documents

Publication Publication Date Title
WO2000027819A3 (de) Anthranilsäureamide und deren verwendung als arzneimittel
HK1087398A1 (en) 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases
WO2002047668A3 (de) Neue arzneimittelkompositionen auf der basis von anticholinergika und ciclesonide
WO2002008190A3 (de) Neue heteroaryl-derivate und deren verwendung als antitumormittel
WO2004052280A3 (en) Anti-angiogenic compounds and their use in cancer treatment
WO2001045679A3 (de) Verwendung von chemotherapeutika zur topischen behandlung
HK1096392A1 (en) Substituted heterocycles
WO2004006858A3 (en) Compounds, compositions, and methods employing same
ATE427114T1 (de) Verwendung von hepcidin zur herstellung eines arzneimittels zur behandlung von eisenhomíostase stírungen
WO2005063734A3 (de) Substituierte thiophene
EP1251126A3 (de) Fluor-substituierte benzensulfonyl-derivate zur behandlung von entzündungen
AU2001247968A1 (en) Use of asiatic acid or asiaticoside for treatment of cancer
WO2001051044A3 (en) Substances for use in treating psoriasis
HUT68589A (en) The cyclodextrin cluster complexes of taxol, taxotere, or taxus, process for their production, and use of them
AU2002354269A1 (en) Pharmaceutical and foodstuff products comprising deuterium for the treatment of diabetes and methods for production thereof
WO2004074454A3 (en) Methods and compositions for the treatment of cancer and infectious disease using alpha (2) macroglobulin-antigenic molecule complexes
WO2003018568A3 (en) Ascorbic acid derivatives, methods of synthesis and pharmaceutical use thereof
WO2003013498A3 (de) Nitratester-cyclodextrinkomplexe zur behandlung von erkrankungen insbesondere koronarerkrankungen
MY138088A (en) Use of deoxypeganine for treating clinical depression
WO2003024996A3 (de) Antibakterielle makrozyklen
WO2005047278A3 (de) Substituierte dihydrochinazoline ii
WO2000069841A3 (en) Benzofuranylaminoalcohols
AU2003211258A1 (en) Stent for intracranial vascular therapy and process for producing the same
WO2004037278A3 (de) Dyslokalisationsmoleküle und deren verwendung
WO2003031381A3 (fr) Synthese du (z) -3, 5, 4' trimethoxystilbene et son utilisation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BR BY BZ CA CH CN CO CR CU CZ DE DK DZ EC EE ES FI GB GD GE GH GM HR ID IL IN IS JP KE KG KP KR KZ LC LK LS LT LU LV MA MD MG MK MN MW MZ NO NZ OM PH PL PT RO RU SD SE SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2003518507

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002767047

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10483219

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2002767047

Country of ref document: EP